AVZO-103

PreclinicalSmall molecule

AAvenzo Therapeutics, Inc.

AVZO-103 is one of 5 small molecule programs targeting Solid Tumor Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor CancerRecruiting

Solid Tumor CancerPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Solid Tumor Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

1 2

Thalomid

Bristol-Myers Squibb

Phase 2

1 3

Mitomycin C

GGynecologic Oncology Group

Phase 2

1 4

Combination Agent

AAvenzo Therapeutics, Inc.

Preclinical

1 5

AVZO-103

AAvenzo Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Solid Tumor Cancer

NCT07193511

Clinical

Trials by Indication[1]

Solid Tumor Cancer1 trial

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT07193511·355 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AVZO-103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AVZO-103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AVZO-103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avenzo Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAvenzo Therapeutics, Inc.

AVZO-103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Solid Tumor Cancer1 trial

References

Drug Info

Quick Facts

Related News